When should acromegaly be suspected, which investigations are indicated, what is the appropriate management, and which genetic tests should be ordered?

When to Suspect Acromegaly

Suspect acromegaly in any patient with acral and facial features (enlarged hands, feet, coarse facial features), or in patients with a pituitary mass, or in younger patients (<50 years) with primary hyperparathyroidism, multiple comorbidities (sleep apnea, type 2 diabetes, debilitating arthritis, carpal tunnel syndrome, hyperhidrosis, hypertension), or comparing old photographs showing progressive facial changes. 1

Clinical Scenarios Requiring Investigation

High Suspicion - Measure IGF-1 Immediately:

• Typical acromegalic features: Acral enlargement (ring/shoe size increase), frontal bossing, prognathism, macroglossia, interdental separation 1
• Pituitary mass on imaging (any size) 1
• Young age presentations: Primary hyperparathyroidism before age 50, pituitary adenoma before age 30 2

Moderate Suspicion - Consider IGF-1 Testing:

• Multiple associated conditions (≥2 of the following): sleep apnea syndrome, type 2 diabetes mellitus, debilitating arthritis, carpal tunnel syndrome, hyperhidrosis, hypertension 1
• Cardiovascular complications: Heart failure, arrhythmias not age-appropriate 3
• Progressive changes: Serial photographs showing gradual facial coarsening 4

---

How to Investigate

Biochemical Diagnosis Algorithm

Step 1: Initial Screening

Measure serum IGF-1 (age- and sex-normalized reference ranges are critical) 1

• If IGF-1 >1.3× upper limit of normal (ULN): Proceed to confirmatory testing 5
• If IGF-1 elevated but <1.3× ULN or equivocal: Repeat IGF-1 using same assay, consider oral glucose tolerance test 5
• If IGF-1 normal: Acromegaly unlikely (but repeat if high clinical suspicion)

Critical pitfall: Do NOT rely on random GH levels for diagnosis - GH is pulsatile and unreliable 1. Random fasting GH may inform prognosis but is not diagnostic 5.

Step 2: Confirmatory Testing

Oral glucose tolerance test (OGTT): Administer 75g glucose load

• Diagnostic criterion: Failure to suppress GH to <1 μg/L (or <0.4 ng/mL with ultrasensitive assays) during documented hyperglycemia 1
• Measure GH at 0,30,60,90,120 minutes
• This confirms autonomous GH secretion

Important: Use the same GH and IGF-1 assay throughout diagnosis and follow-up due to significant interassay variability 1, 6

Step 3: Imaging

Once biochemically confirmed, obtain pituitary MRI with gadolinium to visualize the adenoma 1

• Identifies tumor size, location, and invasion
• Guides surgical planning
• CT if MRI contraindicated

Step 4: Comorbidity Assessment

Evaluate all patients for associated complications 1:

• Cardiovascular: Echocardiogram, ECG, blood pressure monitoring
• Metabolic: Fasting glucose, HbA1c, lipid panel
• Colonoscopy at diagnosis (increased colon neoplasia risk) 1
• Sleep study if symptoms suggest sleep apnea 1
• Thyroid ultrasound if palpable nodules 1
• Pituitary function testing: Assess for hypopituitarism (TSH, free T4, cortisol, testosterone/estradiol, prolactin) 1

---

How to Manage

Treatment Algorithm

Primary Therapy

Transsphenoidal surgery is the first-line treatment for most patients 1

• Refer to experienced pituitary neurosurgeon (outcomes are operator-dependent)
• Consider preoperative medical therapy with somatostatin analogues for large/invasive tumors
• Repeat surgery should be considered for residual intrasellar disease after initial operation 1

Biochemical Treatment Goals

• Primary target: Age-normalized serum IGF-1 1
• Secondary target: Random GH <1.0 μg/L correlates with disease control 1
• These targets reduce mortality and improve quality of life 7

Medical Therapy (Post-surgical or Primary if Surgery Not Feasible)

First-line medical therapy: First-generation somatostatin receptor ligands (octreotide LAR, lanreotide)

• Start if surgery fails to achieve biochemical control
• Can be primary therapy if surgery contraindicated or patient refuses 3, 7

Second-line options for inadequate response:

• Pasireotide (second-generation somatostatin analogue)
• Pegvisomant (GH receptor antagonist) - particularly effective for normalizing IGF-1
• Cabergoline (dopamine agonist) - especially if mild elevation or prolactin co-secretion
• Combination therapy: Somatostatin analogue + pegvisomant or + cabergoline 3, 7

Radiation therapy: Reserved for patients with persistent disease despite surgery and medical therapy 7

Long-term Monitoring

• IGF-1 levels every 3-6 months until stable, then annually
• Pituitary MRI periodically to assess tumor size
• Ongoing comorbidity management: Cardiovascular disease, diabetes, arthritis, sleep apnea require aggressive treatment 1
• Repeat colonoscopy per guidelines (increased surveillance due to polyp risk) 1

---

When and What to Send for Genetics

Indications for Genetic Testing

Order genetic testing in the following scenarios 8, 9, 10:

Strong Indications:

• Age <30 years at diagnosis (especially gigantism/childhood-onset) 10
• Family history of pituitary adenomas or endocrine tumors 2, 9
• Multiple endocrine lesions: Hyperparathyroidism + pituitary adenoma, or other MEN1 features 2
• Gigantism (childhood/adolescent GH excess) 10
• Macroadenoma before age 30 2
• Multiple pituitary adenomas or aggressive/invasive tumors in young patients 8

Consider Genetic Testing:

• Primary hyperparathyroidism before age 50 (screen for MEN1) 2
• Recurrent hyperparathyroidism after surgery 2
• Skin manifestations: Multiple facial angiofibromas, collagenomas, lipomas (suggest MEN1) 2
• Café-au-lait spots with precocious puberty (McCune-Albright syndrome) 9

Specific Genetic Tests to Order

Multi-gene panel testing is preferred over single-gene testing 8, 10:

Primary Genes to Include:

• AIP (aryl hydrocarbon receptor-interacting protein) - most common in familial isolated pituitary adenoma (FIPA), especially young-onset aggressive somatotropinomas 9, 10
• MEN1 - multiple endocrine neoplasia type 1 (parathyroid, pituitary, pancreatic NETs) 2, 9
• GNAS - McCune-Albright syndrome (usually postzygotic mosaic, may need specialized testing) 9, 10
• PRKAR1A - Carney complex (cardiac myxomas, spotty skin pigmentation) 9, 10

Additional Genes in Comprehensive Panels:

• GPR101 - X-linked acrogigantism (Xq26.3 microduplication, requires chromosome microarray or ddPCR) 9, 10
• CDKN1B (MEN4), MAX, SDHA/B/C/D (pheochromocytoma-paraganglioma-pituitary association) 9, 10
• Emerging genes: NF1, PRKACB, PAM, CHEK2 10

Testing Methodology:

• Next-generation sequencing (NGS) multi-gene panel
• Chromosome microarray or droplet digital PCR for GPR101 microduplications 10
• Testing should be performed in clinically accredited laboratories with expertise in pituitary genetics 10

Family Screening:

• If pathogenic variant identified, screen first-degree relatives (even if asymptomatic) 2
• Early detection allows intervention before complications develop, improving outcomes 8

Refer to specialized pituitary center or genetics service for interpretation and family counseling when genetic testing is indicated 5, 10